Highlights Prelude Therapeutics Incorporated

Equities

PRLD

US74065P1012

Real-time Estimate Cboe BZX Other stock markets 07:23:25 18/06/2024 pm IST			5-day change	1st Jan Change
3.865 ^USD	-1.65%		-0.76%	-7.96%

12/06	Transcript : Prelude Therapeutics Incorporated Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 10:40 AM
31/05	Prelude Therapeutics Files for $400 Million Mixed Shelf	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Prelude Therapeutics Files for $400 Million Mixed Shelf	31/05	MT
Prelude Therapeutics Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05	CI
Prelude Therapeutics Incorporated Reports Earnings Results for the Full Year Ended December 31, 2023	16/02	CI
Prelude Therapeutics Incorporated Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	02/11	CI
Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference	14/23/14	CI
Prelude Therapeutics Incorporated Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	03/23/03	CI
Debt Ceiling Deal Hopes Boost Exchange-Traded Funds, Equity Futures Pre-Bell Thursday	18/23/18	MT
Prelude Therapeutics Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2023	08/23/08	CI
Prelude Therapeutics Forms Hematologic Cancer Clinical Trial Partnership with BeiGene	15/23/15	MT
Prelude Therapeutics Incorporated Reports Earnings Results for the Full Year Ended December 31, 2022	15/23/15	CI
Prelude Therapeutics Incorporated Reports Earnings Results for the Full Year Ended December 31, 2022	15/23/15	CI
Prelude Therapeutics Incorporated Announces Clinical Trial Collaboration with BeiGene	15/23/15	CI
Earnings Flash (PRLD) PRELUDE THERAPEUTICS Reports Q3 Loss $-0.63	14/22/14	MT
Prelude Therapeutics Incorporated Reports Earnings Results for the Third Quarter Ended September 30, 2022	14/22/14	CI
Prelude Therapeutics Incorporated Receives FDA Clearance of IND for PRT3789, a Potent and Selective First-in-Class SMARCA2 Protein Degrader	18/22/18	CI
PRELUDE THERAPEUTICS INC Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	09/22/09	AQ
Prelude Therapeutics Incorporated Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	09/22/09	CI
PRELUDE THERAPEUTICS INC Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	10/22/10	AQ
Earnings Flash (PRLD) PRELUDE THERAPEUTICS Posts Q1 Loss $-0.63	10/22/10	MT
Prelude Therapeutics Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2022	10/22/10	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Prelude Therapeutics Incorporated

Equities

PRLD

US74065P1012

Highlights

Filters